Ed Kensik06.29.06
Hayward, CA-based Aradigm announced Thursday that its request for a hearing to appeal the Nasdaq’s decision to delist its stock has been granted.
Nasdaq has stayed the delisting of the company's stock until the hearing, which is scheduled for Aug. 3, according to the company that combines its non-invasive delivery systems with novel formulations to create products that enable patients to comfortably self-administer biopharmaceuticals and small molecule drugs.
The stock exchange delisted the company’s securities as a result of the company’s failure to comply with Nasdaq’s continued listing requirements.